Study examines benefits of SGLT2 inhibitors in individuals with type 1 diabetes

In addition to lowering blood sugar levels, diabetes drugs called sodium-glucose cotransporter 2 (SGLT2) inhibitors can provide kidney- and cardiovascular-related benefits for people with type 2 diabetes. A recent study examined whether such benefits are also experienced by individuals with type 1 diabetes. The findings will be presented online at ASN Kidney Week 2021 November 4–November 7.

The study applied the Steno Type 1 Risk Engines, validated prediction models for cardiovascular disease and kidney failure in people with type 1 diabetes, to 3,660 adults with type 1 diabetes who were treated from 2001 to 2016. Use of SGLT2 inhibitors was linked with a 6.1% lower risk of cardiovascular disease over 5 years (with up to an 11.1% lower risk in individuals with signs of kidney disease) and with a 5.3% lower risk of kidney failure (with up to a 7.6% lower risk in those with signs of kidney disease).

In our study, we have shown significant risk reductions for cardiovascular disease and kidney failure with SGLT2 inhibitor treatment in type 1 diabetes. Our model provides an estimate of benefit that may balance the risks associated with use of SGLT2 inhibitors in type 1 diabetes."

Elisabeth Stougaard, PhD, Lead Author, Steno Diabetes Center, Copenhagen

Study: "Sodium–glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines"

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Study reveals extra burden of COVID-19 adverse events in end-stage kidney disease patients